ZNO Shares Zoono Group Limited
ASX · ASXLast in our picks 2026-10-19 — not in the current list; analysis below is from that screen
Specialty technology commercialization offers optionality, though liquidity and evidence of momentum remain limited.
Signal breakdown
- ▸Speculative commercialization catalyst and thin liquidity
- ▾Below 50-day MA (-5.58%)
- ▸Volume 8.4× average — accumulation
- ▾Near 52-week low (6.6% of range)
Is ZNO a buy right now?
Trend: ZNO is trading below the 50-day average (-6.00%), RSI 40 — neutral momentum, with a 3-month return of -4.08%.
Valuation & quality: Zoono Group Limited trades on PEG 1.78, price-to-book 6.44; fundamentals show net margin -107.0%, return on equity -54.6%, revenue growth 125.7% year on year.
Our screen: ACCUMULATE (score 1) — Specialty technology commercialization offers optionality, though liquidity and evidence of momentum remain limited.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +0.00% | +16.70% | +0.00% | -28.60% | +0.00% | +0.00% | +0.00% | +0.00% |
Fundamentals
Technical signals
About Zoono Group Limited
Zoono Group Limited, together with its subsidiaries, engages in the research, development, and sale of a range of antimicrobial products in New Zealand, Australasia, Asia, the United States, India, the United Kingdom, and Europe.
Sector: Consumer Defensive · Industry: Household & Personal Products · New Zealand · Website
Related Communication Services picks
Browse: all ASX stocks · Communication Services picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.